By David S. MacDougall
GOTHENBURG, Sweden — October 19, 2010 — The prevalence and severity of fatigue in patients with relapsing-remitting multiple sclerosis (RRMS) are more reduced during treatment with natalizumab versus interferon beta (IFNb) or glatiramer acetate (GA), according to a study presented here at the 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).
Fatigue is one of the hallmark symptoms of MS and is associated with severe impairment of quality of life, noted Norman Putzki, MD, Cantonal Hospital, St. Gallen, Switzerland, on October 15.
In the study, 49 patients with RRMS who were treated with natalizumab were compared with 53 matched patients who had been treated with IFNb or GA. Some of the patients treated with natalizumab had previously been treated with IFN, GA, or mitoxantrone, and others had received no previous treatment.
Treatment efficacy was based on the Fatigue Severity Scale (FSS), Modified Fatigue Impact Scale (MFIS) score, and WHO-Five Well-Being Index (WHO-5) scores.
Continue reading
GOTHENBURG, Sweden — October 19, 2010 — The prevalence and severity of fatigue in patients with relapsing-remitting multiple sclerosis (RRMS) are more reduced during treatment with natalizumab versus interferon beta (IFNb) or glatiramer acetate (GA), according to a study presented here at the 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).
Fatigue is one of the hallmark symptoms of MS and is associated with severe impairment of quality of life, noted Norman Putzki, MD, Cantonal Hospital, St. Gallen, Switzerland, on October 15.
In the study, 49 patients with RRMS who were treated with natalizumab were compared with 53 matched patients who had been treated with IFNb or GA. Some of the patients treated with natalizumab had previously been treated with IFN, GA, or mitoxantrone, and others had received no previous treatment.
Treatment efficacy was based on the Fatigue Severity Scale (FSS), Modified Fatigue Impact Scale (MFIS) score, and WHO-Five Well-Being Index (WHO-5) scores.
Continue reading
***********************************************************
“Providing You with ‘MS Views and News’, is what we do“
Keep Informed and up–to–date with information concerning
Multiple Sclerosis when registered at
the MS Views and News website.
****************************************************************
Disclaimer: ‘MS Views and News’ (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
. ****************************************************************
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews